|
|
![]() | ![]() | ![]() | ![]() |
Humana 8-K 2009
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported April 1, 2009
Humana Inc. (Exact Name of Registrant as Specified in Its Charter)
Delaware (State or Other Jurisdiction of Incorporation)
502-580-1000 (Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
On April 7, 2009, Humana Inc. (the Company) announced that Jonathan T. Lord, M.D., Senior Vice President Chief Innovation Officer, will leave the Company to become Chief Executive Officer of Navigenics, Inc. A copy of the press release related to the announcement is attached hereto as Exhibit 99 and is incorporated by reference herein.
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: April 7, 2009 INDEX TO EXHIBITS
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||